350 rub
Journal Technologies of Living Systems №8 for 2010 г.
Article in number:
Matrix metalloproteinases and clinico-morphological characteristic of ovarian neoplasms
Keywords: matrix metalloproteinase 2 matrix metalloproteinase 7 matrix metalloproteinase 9 matrix metalloproteinase tissue inhibitor type 1 ovarian neoplasms
Authors:
N.E. Kushlinsky, E.S. Gershtein, N.V. Levkina, D.N. Kushlinsky, I.V. Tereshkina, K.P. Laktionov K.P., L.V. Adamiyan
Abstract:
Matrix metalloproteinase (MMP) 7 and 9 levels were significantly increased and MMP-2 level was decreased in ovarian cancer tissue as compared to benign tumors. MMP-7, MMP-9 and TIMP-1 concentrations in blood serum of ovarian cancer patients was significantly higher, and MMP-2 level - significantly lower than in control group of healthy women. In the patients examined after presurgical therapy а comparative normalization of all parame-ters studied both in the tumors, and in serum was observed. Significant positive association between MMP-7, MMP-9 and TIMP-1 serum levels and tumor size determined by ultrasound examination, and a positive correlation between these markers and CA125 serum values were demonstrated in ovarian cancer patients.
Pages: 52-57
References
  1. Ашрафян Л.А., Киселев В.И.Опухоли репродуктивных органов (этиология и патогенез). М.: Изд-во «Династия». 2007. 208 c.
  2. Новикова Е.Г., Ронина Е.А., Корнеева И.А. // Злокачественные опухоли яичников. Онкология. Национальное руководство / под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЕОТАР Медиа. 2008. C. 812-819.
  3. Хохлова С.В.Новый взгляд на лечение рака яичников // Опухоли женской репродуктивной системы. 2010. № 1. C. 68 -71.
  4. Bast R. Updates on early detection and risk stratification for ovarian cancer. 38th Meeting of the International Society of Oncology and BioMarkers (ISOBM) (Munchen, September 3-8, 2010) // Tumor Biology. 2010. V. 31. Suppl.1. P. 122-123.
  5. Cai K.Q., Yang W.L., Capo-Chichi C.D.et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis // Mol. Carcinog. 2007. V. 46. № 2. P. 130-143.
  6. Chobanian N., Dietrich C.S. Ovarian cancer // Surg. Clin. North Am. 2008. V. 88. P.285-299.
  7. Demeter A., Sziller I., Csapo Z. et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer // Anticancer Res. 2005. V. 25Б. № 4. P. 2885-2889.
  8. Deryugina E.I., Quigley J.P.Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev. 2006. V. 25Б. № 1. P. 9-34.
  9. Duhoux F.P., Machiels J.-P.Antivascular Therapy for Epithelial Ovarian Cancer // J. Oncology. 2009. V. 2010. Р. 1-16.
  10. Goodman M.T., Shvetsov Y.B. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004 // Cancer Epidemiol Biomarkers Prev. 2009. V. 18. №.1. Р. 132-139.
  11. Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors // Gynecol Oncol. 2000. V. 77. № 3. P. 369-376.
  12. Kamat A.A., Fletcher M., Gruman L.M. et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer // Clin. Cancer Res. 2006. V. 12. № 6. P. 1707-1714.
  13. Kurman R.J., Visvanathan K., Roden R., Wu T.C., Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis // Am. J. Obstet. Gynecol. 2008. V. 198. № 4. Р.351-356.
  14. Liotta L.A., Tryggvason K., Garbisa S.et al.Metastatic potential correlates with enzymatic degradation of basement membrane collagen // Nature. 1980. V. 284. № 5751. P. 67-68.
  15. Maatta M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours // Anticancer Res. 2007. V. 27. № 4C. P. 2753-2758.
  16. Malemud C.J.Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. V. 11. P. 1696-1701.
  17. Ozalp S., Tanir H.M., Yalcin O.T. et al. Prognostic value of matrix metalloprotei­nase-9 (gelatinase-B) expression in epi­thelial ovarian tumors // Eur. J. Gynae­col. Oncol. 2003. V. 24. № 5. P. 417-420.
  18. Perigny M., Bairati I., Harvey I. et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer // Am. J. Clin. Pathol. 2008. V. 129. № 2. P. 226-231.
  19. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. № 2. P. 96-102.
  20. Rauvala M., Puistola U., Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor // Gynecol. Oncol. 2005.
    V. 99. № 3. P. 656-663.
  21. Rauvala M., Turpeenniemi-Hujanen T., Puistola U. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer // Anticancer Res.2006. V. 26. № 6C. P. 4779-4784.
  22. Sillanpaa S., Anttila M., Suhonen K. et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer // Tumour Biol. 2007. V. 28. № 5. P. 280-289.
  23. Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer // Gynecol. Oncol. 2007. V. 104. № 2. P. 296-303.
  24. Sillanpaa S.M., Anttila M.A., Voutilainen K.A. et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression // Int. J. Cancer. 2006. V. 119. № 8. P. 1792-1799.
  25. Zaman K., Driscoll R., Hahn D. et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy // Int. J. Cancer. 2006. V. 118. № 3. P. 755-764.